Advisory Committee Meeting | Virtual

Event Title

April 4-5, 2023: Science Advisory Board to the National Center for Toxicological Research 2023 Meeting Announcement

April 4 - 5, 2023

Scheduled

Date:: April 4 - 5, 2023
Day1:: Tue, Apr 04 9:00 a.m. - 06:55 p.m. ET
Day2:: Wed, Apr 05 9:00 a.m. - 12:30 p.m. ET

What is an advisory committee?

Advisory committees provide independent expert advice to the FDA on broad scientific topics or on certain products to help the agency make sound decisions based on the available science. Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so. Please see, "Advisory Committees Give FDA Critical Advice and the Public a Voice," for more information.

What is an advisory committee?

Summary

The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Science Advisory Board
to the National Center for Toxicological Research. The general function of the committee is to provide advice and recommendations to the Agency on research being conducted at the National Center for Toxicological Research (NCTR). At least one portion of the meeting will be closed to the public.

Dates

The meeting will be held on April 4, 2023, from 9 a.m. to 6:55 p.m. Eastern Time and April 5, 2023, from 9 a.m. to 12:30 p.m. Eastern Time.

Address

Please note that due to the impact of this COVID–19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform. Answers to commonly asked questions about FDA advisory committee meetings may be accessed at: Common Questions and Answers about FDA Advisory Committee Meetings | FDA.

Webcast Information

The meeting will be webcast both days and will be available at the following links:

Meeting Day 1:
Link: https://fda.zoomgov.com/j/1608491479?pwd=cStKYmZUdDB5RjR1YWZCTW1kcDY2dz09
Passcode: v0W1q#

Meeting Day 2:
Link: https://fda.zoomgov.com/j/1604896182?pwd=OU1McUNMUWhBbUlFMkhLYlpHS1JSdz09
Passcode: pW+iT4

For Further Information Contact

Donna Mendrick
National Center for Toxicological Research, Food and Drug Administration
10903 New Hampshire Ave.
Bldg. 32, Rm. 2208
Silver Spring, MD 20993–0002
301–796–8892

FDA Advisory Committee Information Line
1–800–741–8138 (301–443–0572 in the Washington, DC area)

A notice in the Federal Register about last-minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency’s website at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

Supplementary Information

Agenda

On April 4, 2023, the Science Advisory Board Chair will welcome the participants, and the NCTR Director will provide a Center-wide update on scientific initiatives and accomplishments during the past year. The Science Advisory Board will be presented with an overview of the Science Advisory Board Subcommittee Site Visit Report and a response to this review. The Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, Center for Devices and Radiological Health, Center for Food Safety and Applied Nutrition, Center for Tobacco Products, and the Office of Regulatory Affairs will each briefly discuss their specific research strategic needs and potential areas of collaboration.

On April 5, 2023, there will be updates from the NCTR Research Divisions and a public comment session. Following an open discussion of all the information presented, the open session of the meeting will close so the Science Advisory Board members can discuss personnel issues at NCTR.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s website after the meeting. Background material is available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting link.

Procedure

On April 4, 2023, from 9 a.m. to 6:55 p.m. Eastern Time and April 5, 2023, from 9 a.m. to 12:30 p.m. Eastern Time, the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before March 28, 2023. Oral presentations from the public will be scheduled between approximately 2 p.m. to 3 p.m. Eastern Time. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before March 20, 2023. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by March 21, 2023.

Closed Committee Deliberations

On April 5, 2023, from 2 p.m. to 3 p.m. Eastern Time, the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). This portion of the meeting will be closed to permit discussion of information concerning individuals associated with the research programs at NCTR.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Donna Mendrick at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website at Public Conduct During FDA Advisory Committee Meetings | FDA for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: January 27, 2023.

Lauren K. Roth,
Associate Commissioner for Policy.

A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s website or call the committee’s Designated Federal Officer (see Contact Information) to learn about possible modifications before coming to the meeting.

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact the committee’s Designated Federal Officer (see Contact Information) at least 7 days in advance of the meeting.

Answers to commonly asked questions including information regarding special accommodations due to a disability may be accessed at: Common Questions and Answers about FDA Advisory Committee Meetings.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at Public Conduct During FDA Advisory Committee Meetings for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).

Event Materials

Title	File Type/Size	Source Organization
2023 Science Advisory Board to NCTR Meeting Agenda (Central)	pdf (177.41 KB)
2023 Science Advisory Board to NCTR Meeting Agenda (Eastern)	pdf (183.46 KB)